 Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 6 | 6 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 5 | 5 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 6 | 6 | | 2008 | 3 | 8 | 11 | | 2009 | 1 | 14 | 15 | | 2010 | 1 | 14 | 15 | | 2011 | 2 | 13 | 15 | | 2012 | 2 | 23 | 25 | | 2013 | 2 | 18 | 20 | | 2014 | 0 | 19 | 19 | | 2015 | 3 | 25 | 28 | | 2016 | 5 | 24 | 29 | | 2017 | 2 | 38 | 40 | | 2018 | 6 | 30 | 36 | | 2019 | 1 | 29 | 30 | | 2020 | 1 | 33 | 34 | | 2021 | 1 | 15 | 16 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 | | 2024 | 8 | 19 | 27 | | 2025 | 0 | 34 | 34 | | 2026 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Figueroa V, Coianis MI, Sahores A, Pataccini G, Abba MC, Elía A, May M, Vanzulli SI, Martínez Vázquez P, Burruchaga J, Torres F, Sartorius CA, Lanari C, Lamb CA. Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. Br J Cancer. 2026 Jun; 134(11):1671-1682.
-
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ. Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer Res. 2026 Apr 02; 86(7):1605-1621.
-
Cardus O, Mañé Pujol J, de Daniel A, Moreno DF, Oliveira TGM, Battram AM, Salsench SV, Perez-Amill L, Llobregat H, Carpio Mármol J, Martin-Antonio B, Oliver-Caldes A, Munárriz D, Juan M, Urbano-Ispizua A, Rodríguez-Lobato LG, Fernández de Larrea C. Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. J Immunother Cancer. 2026 Mar 03; 14(3).
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM. Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. Mol Cancer Ther. 2026 Jan 02; 25(1):48-70.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Wang D, Ritz C, Luo Y, Suresh A, Pierce A, Veo B, Brunt B, Dahl N, Serkova N, Venkataraman S, Danis E, Kus K, Mazan M, Rzymski T, Vibhakar R. Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. Nat Commun. 2025 Dec 16; 16(1):11152.
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|